Efficacy

Ubrelvy (Ubrogepant) for Migraine

Ubrelvy, with the active ingredient ubrogepant, is an oral medication approved by the FDA for the acute treatment of migraine with or without aura in adults. As a member of the class of drugs known as CGRP receptor antagonists, ubrogepant works by blocking the calcitonin gene-related peptide (CGRP) receptor, which is believed to play a critical role in migraine. Clinical trials have demonstrated the efficacy of ubrogepant in relieving migraine pain and the most bothersome symptoms associated with migraine attacks when taken at the onset of an episode. Patients in these studies reported significant pain relief and reduction in symptoms such as nausea, light sensitivity, and sound sensitivity compared to placebo.

The efficacy of Ubrelvy was evaluated in two pivotal phase 3 clinical trials, ACHIEVE I and ACHIEVE II. These trials showed that a significant percentage of patients experienced pain freedom at two hours after taking a single dose of ubrogepant compared to those who took a placebo. Additionally, many patients were able to return to normal function within two hours, and the medication was also effective in treating migraines that were moderate to severe in intensity. The benefits of ubrogepant were observed without the need for a second dose for the majority of patients.

Trudhesa (Dihydroergotamine Mesylate) for Migraine

Trudhesa, which contains dihydroergotamine mesylate (DHE), is a nasal spray approved for the acute treatment of migraine with or without aura in adults. DHE is a well-established treatment for migraine that has been used for decades. Trudhesa utilizes a proprietary nasal delivery system designed to improve the absorption and distribution of DHE in the nasal cavity, potentially leading to rapid onset of action. Clinical studies have shown that Trudhesa can effectively relieve migraine pain and symptoms. Patients using Trudhesa reported pain relief, with some experiencing relief as early as 15 minutes after administration, and sustained relief for up to 48 hours post-dose.

While Trudhesa's efficacy in relieving migraine pain and symptoms is well-documented, it is important to note that individual responses to treatment can vary. In clinical trials, Trudhesa was shown to be effective in providing relief for both mild and severe migraine attacks. Additionally, Trudhesa has been found to be beneficial for patients who have not responded adequately to other migraine medications, offering an alternative for those seeking different treatment options. The nasal spray delivery system also provides a non-oral route of administration, which can be particularly useful for patients who experience nausea and vomiting during migraine attacks.